BR112022001125A2 - Compostos macrocíclicos como agonistas de sting, seus métodos e seus usos - Google Patents

Compostos macrocíclicos como agonistas de sting, seus métodos e seus usos

Info

Publication number
BR112022001125A2
BR112022001125A2 BR112022001125A BR112022001125A BR112022001125A2 BR 112022001125 A2 BR112022001125 A2 BR 112022001125A2 BR 112022001125 A BR112022001125 A BR 112022001125A BR 112022001125 A BR112022001125 A BR 112022001125A BR 112022001125 A2 BR112022001125 A2 BR 112022001125A2
Authority
BR
Brazil
Prior art keywords
methods
macrocyclic compounds
sting agonists
compounds
macrocyclic
Prior art date
Application number
BR112022001125A
Other languages
English (en)
Inventor
Kumar Das Amit
Sahebrao Walke Deepak
Rajaram Jadhav Ganesh
Moloy Banerjee
Popat Karche Navnath
Ramnivasji Gupta Nishant
Kumar Kamboj Rajender
Aditya Bhoskar Smita
Madhukar Kalhapure Vaibhav
P Palle Venkata
Vidya Ramdas
Popatrao Vyavahare Vinod
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of BR112022001125A2 publication Critical patent/BR112022001125A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

compostos macrocíclicos como agonistas de sting, seus métodos e seus usos. são descritos compostos macrocíclicos tendo a fórmula geral (i) ou (ii), e suas formas tautoméricas, estereo-isômeros, sais farmaceuticamente aceitáveis, hidratos, solvatos e pró-fármacos dos mesmos, sua combinação com medicamentos adequados, processos correspondentes para a síntese, composições farmacêuticas, e usos dos compostos aqui descritos.
BR112022001125A 2019-07-22 2020-07-22 Compostos macrocíclicos como agonistas de sting, seus métodos e seus usos BR112022001125A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201921029556 2019-07-22
IN201921051086 2019-12-10
IN202021003961 2020-01-29
PCT/IB2020/056875 WO2021014365A1 (en) 2019-07-22 2020-07-22 Macrocyclic compounds as sting agonists and methods and uses thereof

Publications (1)

Publication Number Publication Date
BR112022001125A2 true BR112022001125A2 (pt) 2022-03-15

Family

ID=72422197

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001125A BR112022001125A2 (pt) 2019-07-22 2020-07-22 Compostos macrocíclicos como agonistas de sting, seus métodos e seus usos

Country Status (20)

Country Link
US (1) US20220289763A1 (pt)
EP (1) EP4004002B1 (pt)
JP (1) JP2022541330A (pt)
KR (1) KR20220035955A (pt)
CN (1) CN114174303B (pt)
AU (1) AU2020319058A1 (pt)
BR (1) BR112022001125A2 (pt)
CA (1) CA3147397A1 (pt)
CL (1) CL2022000145A1 (pt)
CO (1) CO2022001814A2 (pt)
CR (1) CR20220029A (pt)
DK (1) DK4004002T3 (pt)
EC (1) ECSP22005485A (pt)
FI (1) FI4004002T3 (pt)
GE (1) GEP20247627B (pt)
IL (1) IL289740A (pt)
MX (1) MX2022000939A (pt)
PE (1) PE20220937A1 (pt)
WO (1) WO2021014365A1 (pt)
ZA (1) ZA202201375B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022001931A2 (pt) 2019-08-02 2022-06-21 Mersana Therapeutics Inc Derivados de bis-[n-((5-carbamoil)-1h-benzo[d]imidazol-2-il)-pirazol-5-carboxamida e compostos relacionados como agonistas de sting (estimulador de genes de interferon) para o tratamento de câncer
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
AU2022208054A1 (en) * 2021-01-15 2023-07-27 Seagen Inc. Immunomodulatory antibody-drug conjugates
JP2024511832A (ja) * 2021-03-30 2024-03-15 ジャコバイオ ファーマスーティカルズ カンパニー リミテッド Ｓｔｉｎｇアゴニストとして有用な新規化合物およびその使用
WO2024130341A1 (en) * 2022-12-22 2024-06-27 Aculeus Therapeutics Pty Ltd Benzimidazole derivatives for the modulation of sting

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20010395A1 (it) 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
AR046959A1 (es) 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
US7488736B2 (en) 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
BRPI0617165B1 (pt) 2005-10-07 2023-10-03 Exelixis Inc Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
EP2054392A2 (en) 2006-06-15 2009-05-06 Boehringer Ingelheim International GmbH 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase c-alpha
WO2008090570A1 (en) 2007-01-25 2008-07-31 Panacea Biotec Ltd Novel antimicrobials
TW201000447A (en) 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
WO2011091446A1 (en) * 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
WO2012083053A2 (en) * 2010-12-15 2012-06-21 Abbott Laboratories Anti-viral compounds
WO2014104272A1 (ja) 2012-12-28 2014-07-03 日本臓器製薬株式会社 ケイ皮酸アミド誘導体
JP6462006B2 (ja) * 2014-06-04 2019-01-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｓｔｉｎｇのモジュレーターとしての環式ジヌクレオチド
US20180147187A1 (en) 2015-01-12 2018-05-31 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
EP3325473A4 (en) 2015-07-22 2019-06-26 The Royal Institution for the Advancement of Learning / McGill University Compounds and uses thereof in the treatment of cancer and other medical disorders
NZ745957A (en) 2016-04-07 2020-07-31 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
AU2017247806B2 (en) 2016-04-07 2019-11-14 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
JP7008064B2 (ja) 2016-05-27 2022-01-25 杭州英創医薬科技有限公司 Ｆｇｆｒ４阻害剤としてのヘテロ環式化合物
EA036338B1 (ru) * 2017-02-22 2020-10-28 Глэксосмитклайн Интеллекчуал Проперти Девелопмент Лимитед Гетероциклические амиды, пригодные в качестве модуляторов белков
MX2019015468A (es) 2017-06-22 2020-08-03 Curadev Pharma Ltd Moduladores de moleculas pequeñas de sting humana.
US20200172483A1 (en) 2017-06-22 2020-06-04 Curadev Pharma Limited Heterocyclic small molecule modulators of human sting
EP3642184A1 (en) 2017-06-22 2020-04-29 Curadev Pharma Limited Small molecule modulators of human sting
WO2019023635A1 (en) 2017-07-27 2019-01-31 Stingray Therapeutics, Inc. SUBSTITUTED 3 H-IMIDAZO (4,5-C) PYRIDINE AND 1H-PYRROLO (2,3-C) PYRIDINE SERIES OF A NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR A GENE MODULATOR INTERFERON (STING) AS IMMUNOTHERAPEUTIC AGENTS AGAINST CANCER
MA49773A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b
EP3661498A4 (en) 2017-08-04 2021-04-21 Merck Sharp & Dohme Corp. BENZO [B] THIOPHEN STING ANTAGONISTS FOR CANCER TREATMENT
CA3077337A1 (en) * 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
WO2019069269A1 (en) * 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited INTERFERON GENE STIMULATOR MODULATORS USEFUL IN THE TREATMENT OF HIV
WO2020132582A1 (en) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Sting agonists and uses thereof
CR20210495A (es) * 2019-03-28 2021-10-18 Lupin Ltd Compuestos macrocíclicos como agonistas de sting

Also Published As

Publication number Publication date
US20220289763A1 (en) 2022-09-15
ECSP22005485A (es) 2022-02-25
IL289740A (en) 2022-03-01
JP2022541330A (ja) 2022-09-22
DK4004002T3 (da) 2024-09-30
EP4004002B1 (en) 2024-07-10
PE20220937A1 (es) 2022-05-31
MX2022000939A (es) 2022-04-06
ZA202201375B (en) 2022-09-28
AU2020319058A1 (en) 2022-02-17
CR20220029A (es) 2022-03-14
CO2022001814A2 (es) 2022-04-29
EP4004002A1 (en) 2022-06-01
GEP20247627B (en) 2024-05-27
KR20220035955A (ko) 2022-03-22
FI4004002T3 (fi) 2024-10-04
WO2021014365A1 (en) 2021-01-28
CN114174303B (zh) 2024-06-25
CA3147397A1 (en) 2021-01-28
CL2022000145A1 (es) 2022-09-09
CN114174303A (zh) 2022-03-11

Similar Documents

Publication Publication Date Title
BR112022001125A2 (pt) Compostos macrocíclicos como agonistas de sting, seus métodos e seus usos
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
BR112022008375A2 (pt) Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste
CY1124652T1 (el) Παραγωγα 1η-ινδαζολο-3-καρβοξαμιδιου και σχετικες ενωσεις ως αναστολεις παραγοντα d για τη θεραπεια νοσων που χαρακτηριζονται απο μη φυσιολογικη δραστηριοτητα συστηματος συμπληρωματος, οπως π.χ. ανοσολογικες διαταραχες
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
CY1121195T1 (el) Παραγωγα τετραϋδροναφθαλενιου που αναστελλουνπρωτεϊνη mcl-1
CY1122046T1 (el) Δικυκλικα ετεροκυκλικα παραγωγα ως αναστολεις βρομοτομεων
CA3057882A1 (en) Substituted dihydro-spiro-napthalene-oxa derivatives and pharmaceutical compositions thereof useful as inhibitors of mcl-1 protein
BR112021022659A2 (pt) Compostos triarílicos para o tratamento de doenças pd-l1
BR112021018947A2 (pt) Compostos macrocíclicos como agonistas de sting
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
NZ763551A (en) Compounds useful for inhibiting cdk7
BR112022007867A2 (pt) Degradadores de pequena molécula de helios e métodos de uso
BR112016016844A2 (pt) Compostos heterocíclicos
WO2019165043A3 (en) Indane-amines as pd-l1 antagonists
CR20220251A (es) Nuevos derivados de metilquinazolinona
CO2021006482A2 (es) Ureas cíclicas
BR112021017620A2 (pt) Compostos macrocíclicos
BR112017023147A2 (pt) azabenzimidazóis e seu uso como moduladores do receptor de ampa
BR112019004254A2 (pt) inibidores da dopamina-b-hidroxilase penetrantes da barreira hematoencefálica
BR112023019435A2 (pt) Inibidores de nek7
CO2020004977A2 (es) Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
BR112018074985A2 (pt) composições antibacterianas
BR112017022958A2 (pt) métodos para tratamento de câncer com inibidor da via da stat3 e inibidor de quinase